Abstract
CHEK2 gen encodes cell cycle checkpoint kinase 2 that participates in the DNA repair pathway, cell cycle regulation and apoptosis. Mutations in CHEK2 gene may result in kinase inactivation or reduce both catalytic activity and capability of binding other proteins. Some studies indicate that alterations in CHEK2 gene confers increase the risk of breast cancer and some other malignancies, while the results of other studies are inconclusive. Thus the significance of CHEK2 mutations in aetiology of breast cancer is still debatable. The aim of our study was to evaluate the relationship between the breast/ovarian cancer and CHEK2 variants by: i) the analysis of the frequency of selected CHEK2 variants in breast and ovarian cancer patients compared to the controls; ii) evaluation of relationships between the certain CHEK2 variants and clinico-histopathological and pedigree data. The study was performed on 284 breast cancer patients, 113 ovarian cancer patients and 287 healthy women. We revealed the presence of 430T > C, del5395 and IVS2 + 1G > A variants but not 1100delC in individuals from both study and control groups. We did not observe significant differences between cancer patients and controls neither in regard to the frequency nor to the type of CHEK2 variants. We discussed the potential application of CHEK2 variants in the evaluation of breast and ovarian cancer predisposition.
Similar content being viewed by others
References
Allinen M, Huusko P, Mäntyniemi S, Launonen V, Winqvist R (2001) Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer 85:209–212
Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE et al (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528–2531
Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM et al (2007) Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 121:2661–2667
Berliner JL, Fay AM (2007) Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns 16:241–260
Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S, Lazjuk GI, Rogov YI, Dammann O et al (2005) Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer 116:263–266
Brody LC (2002) CHEKs and balances: accounting for breast cancer. Nat Genet 31:3–4
Chekmariova EV, Sokolenko AP, Buslov KG, Iyevleva AG, Ulibina YM, Rozanov ME et al (2006) CHEK2 1100delC mutation is frequent among Russian breast cancer patients. Breast Cancer Res Treat 100:99–102
CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10, 860 breast cancer cases and 9, 065 controls from 10 studies. Am J Hum Genet 74:1175–1182
Cybulski C, Huzarski T, Górski B, Masojć B, Mierzejewski M, Debniak T et al (2004a) A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 64:2677–2679
Cybulski C, Górski B, Huzarski T, Masojć B, Mierzejewski M, Debniak T et al (2004b) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131–1135
Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B et al (2006) A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 43:863–866
Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B et al (2007a) A deletion in CHEK2 of 5, 395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat 102:119–122
Cybulski C, Wokołorczyk D, Kładny J, Kurzawski G, Suchy J, Grabowska E et al (2007b) Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur J Hum Genet 15:237–241
Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK et al (2003) Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72:270–280
Dufault MR, Betz B, Wappenschmidt B, Hofmann W, Bandick K, Golla A et al (2004) Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 110:320–325
Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J (2001a) The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410:842–847
Falck J, Lukas C, Protopopova M, Lukas J, Selivanova G, Bartek J (2001b) Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 20:5503–5510
Fedorova OE, Liubchenko LN, Paiadini IG, Kazubskaia TP, Amosenko FA, Gar'kavtseva RF et al (2007) Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries. Patients of Russian population using biochips. Mol Biol (Mosk) 41:37–42
Friedrichsen DM, Malone KE, Doody DR, Daling JR, Ostrander EA (2004) Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women. Breast Cancer Res 6:629–635
Górski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A et al (2005) Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 92:19–24
Grunkemeier GL, Wu Y, Furnary AP (2009) What is the value of a p value? Ann Thorac Surg 87(5):1337–1343
Kilpivaara O, Vahteristo P, Falck J, Syrjakoski K, Eerola H, Easton D et al (2004) CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 111:543–547
Kleibl Z, Novotny J, Bezdickova D, Malik R, Kleiblova P, Foretova L et al (2005) The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Res Treat 90(2):165–167
Kleibl Z, Havranek O, Novotny J, Kleiblova P, Soucek P, Pohlreich P (2008) Analysis of CHEK2 FHA domain in Czech patients with sporadic breast cancer revealed distinct rare genetic alterations. Breast Cancer Res Treat 112:159–164
Kwiatkowska E, Skasko E, Niwinska A, Wojciechowska-Lacka A, Rachtan J, Molong L et al (2006) Low frequency of the CHEK2*1100delC mutation among breast cancer probands from three regions of Poland. Neoplasma 53:305–308
Li J, Williams BL, Haire LF, Goldberg M, Wilker E, Durocher D et al (2002) Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell 9:1045–1054
Lynch HT, Snyder CL, Lynch JF, Riley BD, Rubinstein WS (2003) Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J Clin Oncol 21:740–753
Nevanlinna H, Bartek J (2006) The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25:5912–5919
Rashid MU, Jakubowska A, Justenhoven C, Harth V, Pesch B, Baisch C et al (2005) German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. Eur J Cancer 41:2896–2903
Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG et al (2003) Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet 72:1023–1028
Seppälä EH, Ikonen T, Mononen N, Autio V, Rökman A, Matikainen MP et al (2003) CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 89:1966–1970
Shaag A, Walsh T, Renbaum P, Kirchhoff T, Nafa K, Shiovitz S et al (2005) Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 14:555–563
Shieh SY, Ahn J, Tamai K, Taya Y, Prives C (2000) The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14:289–300
Sokolenko AP, Rozanov ME, Mitiushkina NV, Sherina NY, Iyevleva AG, Chekmariova EV et al (2007) Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam Cancer 6:281–286
Suspitsin EN, Sherina NY, Ponomariova DN, Sokolenko AP, Iyevleva AG, Gorodnova TV et al (2009) High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients. Hered Cancer Clin Pract 7:5
Szymanska-Pasternak J, Szymanska A, Medrek K, Imyanitov EN, Cybulski C, Gorski B et al (2006) CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol 102:429–431
Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9:321–345
Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295:1379–1388
Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG (2008) CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 26:542–548
Willems PJ (2007) HotSpots Susceptibility genes in breast cancer: more is less? Clin Genet 72:493–496
Wu X, Webster SR, Chen J (2001) Characterization of tumor-associated Chk2 mutations. J Biol Chem 276:2971–2974
Złowocka E, Cybulski C, Górski B, Debniak T, Słojewski M, Wokołorczyk D et al (2008) Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer. Int J Cancer 122:583–586
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Myszka, A., Karpinski, P., Slezak, R. et al. Irrelevance of CHEK2 variants to diagnosis of breast/ovarian cancer predisposition in Polish cohort. J Appl Genetics 52, 185–191 (2011). https://doi.org/10.1007/s13353-010-0013-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13353-010-0013-1